CLAIMS

1. A combination of a first composition and a second composition, wherein the first composition comprises an intact bacterial minicell comprising:

(i) at least one nucleic acid adjuvant molecule packaged within the minicell,

(ii) at least one plasmid comprising a segment that encodes at least one nucleic acid adjuvant molecule packaged within the minicell, and/or

(iii) at least one agonist of a nucleic acid sensor packaged within the minicell,

wherein the at least one nucleic acid adjuvant molecule comprises dsRNA greater than 30 nucleotides in length and less than 1,000 nucleotides in length, and wherein the nucleic acid adjuvant molecule or agonist of a nucleic acid sensor produces an immune response from a target cell; and wherein the at least one agonist of a nucleic acid sensor comprises a polynucleotide product of PNPase1, poly(I:C), poly-ICLC, imiquimod, imidazoquioline resquimod, or CpG-ODNs, and

wherein the second composition comprises an intact bacterial minicell comprising PNU-159682.

2. The combination of the first composition and the second composition of claim 1, wherein the target cell is a:

(a) mammalian immune cell;

(b) human immune cell; or

(c) human immune cell which is a monocytic cell, a macrophage, a T cell, or a dendritic cell.

3. The combination of the first composition and the second composition of claim 1 or 2, wherein:

(a) the at least one nucleic acid adjuvant binds a receptor on the target cell; and/or

(b) the at least one nucleic acid adjuvant comprises a nucleic acid that binds to at least one of TLR3, TLR7, TLR8, TLR9, RIG-I, MDA5, AIM2, cGAS, or IFI16.

4. The combination of the first composition and the second composition of any one of claims 1-3, wherein:

(a) the intact minicell comprises at least two nucleic acid adjuvant molecules; and/or

(b) the intact minicell comprises a nucleic acid adjuvant molecule and an agonist of a nucleic acid sensor.

5. The combination of the first composition and the second composition of any one of claims 1-4, wherein:

(a) the at least one nucleic acid adjuvant molecule comprises a sequence of at least 40 nucleotides;

(b) the at least one nucleic acid adjuvant molecule is a 40-mer; or

(c) the at least one nucleic acid adjuvant molecule is a 50-mer.

6. The combination of the first composition and the second composition of any one of claims 1-5, wherein:

(a) the plasmid comprises a regulatory element operably linked to the segment that encodes at least one nucleic acid adjuvant molecule; and/or

(b) the plasmid encodes multiple nucleic acid adjuvant molecules.

7. The combination of the first composition and the second composition of any one of claims 1-6, further comprising a bispecific ligand, wherein:

(a) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor; and/or

(b) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein the minicell surface structure is an O-

polysaccharide component of a lipopolysaccharide on the minicell surface; and/or

(c) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein the mammalian cell surface receptor is capable of activating receptor-mediated endocytosis of the minicell; and/or

(d) the bispecific ligand comprises an antibody or antibody fragment.

8. The combination of the first composition and the second composition according to any one of claims 1-7, wherein:

(a) the combination comprises fewer than 1 contaminating parent bacterial cell per 10^7 minicells; or

(b) the combination comprises fewer than 1 contaminating parent bacterial cell per 10^8 minicells; or

(c) the combination comprises fewer than 1 contaminating parent bacterial cell per 10^9 minicells; or

(d) the combination comprises fewer than 1 contaminating parent bacterial cell per 10^{10} minicells; or

(e) the combination comprises fewer than 1 contaminating parent bacterial cell per 10^{11} minicells.

9. A combination of the first composition and the second composition according to any one of claims 1-8 for treating a disease in a subject further comprising:

(a) a drug for the treatment of the disease, and/or

(b) a drug for the treatment of the disease to be administered to the subject, wherein the drug is a chemotherapeutic; and/or

(c) a drug for the treatment of the disease to be administered to the subject, wherein the drug is an anti-viral; and/or

(d) a drug for the treatment of the disease to be administered to the subject, wherein the drug is packaged in an intact minicell.

10. Use of a first composition comprising an intact bacterial minicell and a second composition comprising an intact bacterial minicell in the preparation of a combination medicament for treating a disease in a subject, wherein:

(a) the first composition comprises an intact bacterial minicell comprising:

(i) at least one nucleic acid adjuvant molecule packaged within the minicell,

(ii) at least one plasmid comprising a segment that encodes at least one nucleic acid adjuvant molecule packaged within the minicell, and/or

(iii) at least one agonist of a nucleic acid sensor packaged within the minicell,

wherein the at least one nucleic acid adjuvant molecule comprises dsRNA greater than 30 nucleotides in length and less than 1,000 nucleotides in length, and wherein the nucleic acid adjuvant molecule or agonist of a nucleic acid sensor produces an immune response from a target cell, and wherein the at least one agonist of a nucleic acid sensor comprises a polynucleotide product of PNPase1, poly(I:C), poly-ICLC, imiquimod, imidazoquioline resquimod, or CpG-ODNs;

(b) the second composition comprises an intact bacterial minicell comprising PNU-159682;

wherein the intact minicell of the first composition is to be delivered to be in contact with a first target cell to engulf the minicell, and wherein the intact minicell of the second composition is to be delivered to be in contact with a second target cell.

11. The use of claim 10, wherein the first target cell is a:

(a) mammalian immune cell;

(b) human immune cell; or

(c) human immune cell which is a monocytic cell, a macrophage, a T cell, or a dendritic cell.

12. The use of claim 10 or 11, wherein:

(a) the at least one nucleic acid adjuvant binds a receptor on the first target

cell; and/or

(b) the at least one nucleic acid adjuvant comprises a nucleic acid that binds to at least one of TLR3, TLR7, TLR8, TLR9, RIG-I, MDA5, AIM2, cGAS, or IFI16.

13. The use of any one of claims 10-12, wherein the first composition comprises:

(a) the intact minicell comprising at least two nucleic acid adjuvant molecules; and/or

(b) the intact minicell comprising a nucleic acid adjuvant molecule and/or an agonist of a nucleic acid sensor.

14. The use of any one of claims 10-13, wherein:

(a) the at least one nucleic acid adjuvant molecule comprises a sequence of at least 40 nucleotides;

(b) the at least one nucleic acid adjuvant molecule is a 40-mer; or

(c) the at least one nucleic acid adjuvant molecule is a 50-mer.

15. The use of any one of claims 11-14, wherein contact between the minicell and the mammalian cell occurs *in vivo*.

16. The use of any one of claims 10-15, wherein:

(a) the plasmid comprises a regulatory element operably linked to the segment that encodes at least one nucleic acid adjuvant molecule; and/or

(b) the plasmid encodes multiple nucleic acid adjuvant molecules.

17. The use of any one of claims 10-16, wherein the medicament further comprises a bispecific ligand, wherein:

(a) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor; and/or

(b) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein the minicell surface structure is an O-

polysaccharide component of a lipopolysaccharide on the minicell surface; and/or

(c) the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor, wherein the mammalian cell surface receptor is capable of activating receptor-mediated endocytosis of the minicell; and/or

(d) the bispecific ligand comprises an antibody or antibody fragment.

18. The use of claim 17, wherein (d) the bispecific ligand comprises an antibody or antibody fragment and wherein the first target cell is phagocytosis- or endocytosis-competent.

19. The use of any one of claims 10-18, wherein:

(a) the immune response from the first target cell comprises the production of Type I interferon; and/or

(b) the immune response from the first target cell comprises the production of Type I interferon, wherein Type I interferon comprises interferon-α or interferon-β.

20. The use of any one of claims 10-19, wherein the disease is cancer.21. The use of any one of claims 10-20, further comprising:

(a) a drug for the treatment of the disease to be administered to the subject; and/or

(b) a drug for the treatment of the disease to be administered to the subject, wherein the drug is a chemotherapeutic; and/or

(c) a drug for the treatment of the disease to be administered to the subject, wherein the drug is an anti-viral; and/or

(d) a drug for the treatment of the disease to be administered to the subject, wherein the drug is packaged in an intact minicell.

22. The use of any one of claims 10-21, wherein the first composition and the second composition each comprises:

(a) fewer than 1 contaminating parent bacterial cell per 10^7 minicells; or

(b) fewer than 1 contaminating parent bacterial cell per 10^8 minicells; or

(c) fewer than 1 contaminating parent bacterial cell per 10^9 minicells; or

(d) fewer than 1 contaminating parent bacterial cell per 10^{10} minicells; or

(e) fewer than 1 contaminating parent bacterial cell per 10^{11} minicells.

23. A combination of a first composition and a second composition for use in a method of treating a disease in a subject, wherein:

(a) the first composition comprises an intact bacterial minicell comprising:

(i) at least one nucleic acid adjuvant molecule packaged within the minicell,

(ii) at least one plasmid comprising a segment that encodes at least one nucleic acid adjuvant molecule packaged within the minicell, and/or

(iii) at least one agonist of a nucleic acid sensor packaged within the minicell,

wherein the at least one nucleic acid adjuvant molecule comprises dsRNA greater than 30 nucleotides in length and less than 1,000 nucleotides in length, and,

wherein the nucleic acid adjuvant molecule or agonist of a nucleic acid sensor produces an immune response from a target cell; and wherein the at least one agonist of a nucleic acid sensor comprises a polynucleotide product of PNPase1, poly(I:C), poly-ICLC, imiquimod, imidazoquioline resquimod, or CpG-ODNs; and

(b) the second composition comprises an intact bacterial minicell comprising PNU-159682;

wherein the method comprises contacting the target cell with the intact minicell of the first composition, wherein the target cell engulfs the minicell of the first composition.

24. The combination for use according to claim 23, wherein the target cell is a:

(a) mammalian immune cell;

(b) human immune cell; or

(c) human immune cell which is a monocytic cell, a macrophage, a T cell, or a dendritic cell.

25. The combination for use according to claim 23 or 24, wherein:

(a) the at least one nucleic acid adjuvant binds a receptor on the target cell; and/or

(b) the at least one nucleic acid adjuvant comprises a nucleic acid that binds to at least one of TLR3, TLR7, TLR8, TLR9, RIG-I, MDA5, AIM2, cGAS, or IFI16.

26. The combination for use according to any one of claims 23-25, wherein the disease is cancer or an infection.